艾力斯：2025年净利润增长52.55%至21.81亿元，核心产品甲磺酸伏美替尼片销售收入大幅增长

Core Viewpoint - The company reported preliminary financial results for the fiscal year 2025, showing significant growth in both revenue and net profit driven by the sales of its core product, Furmonertinib tablets [1] Financial Performance - The total operating revenue reached 5.172 billion yuan, representing a year-on-year increase of 45.36% [1] - The net profit attributable to the parent company was 2.181 billion yuan, reflecting a year-on-year growth of 52.55% [1] Key Growth Drivers - The substantial increase in revenue and profit was primarily attributed to the significant growth in sales of the core product, Furmonertinib tablets [1] - The company effectively implemented cost-reduction measures, which further enhanced profit levels despite the increase in sales revenue [1]